Sustainability of Eribulin Treatment for Patients with Metastatic Breast Cancer: is the Cost of the Drug Related to the Benefit Produced (Effectiveness and Safety)? a Single Center Experience
Keyword(s):
2015 ◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 1108-1108
2015 ◽
Vol 33
(15_suppl)
◽
pp. e12015-e12015
2014 ◽
Vol 15
(1)
◽
pp. 117-122
◽